Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in B-cell maturation and activation. Genetic variations […]
| Inventor | Institute |
|---|---|
| Margaret Goodall | University of Birmingham |
| Cat. #: | 153223 |
|---|---|
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Application: | IHC |
| Target: | CD21 |
| Reactivity: | Human |
| Clone: | BU80 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Complement receptor type 2; CR2; complement C3d receptor, C3DR, Epstein-Barr virus receptor |
|---|---|
| Product description: | Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in B-cell maturation and activation. Genetic variations are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9) which is a chronic autoimmune disease with an inflammatory, and often febrile multisystemic disorder of connective tissue characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Daudi cell line (B lymphoblast) |
| Target background: | Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in B-cell maturation and activation. Genetic variations are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9) which is a chronic autoimmune disease with an inflammatory, and often febrile multisystemic disorder of connective tissue characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Leucocyte Typing IV, (1989): edited by W. Knapp, OUP, Oxford. Leucocyte Typing V, (1995): edited by S.F. Schlossman, OUP, Oxford. Leucocyte Typing VI, (1998): edited by T. Kishimoto, Garland Publishing, New York. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.